Noema Pharma raised $147 Million in a Series B financing round led by EQT Life Sciences to support its Phase 2 trials for CNS disorders.
Noema Pharma raised $147 Million in a Series B financing round led by EQT Life Sciences to support its Phase 2 trials for CNS disorders.
12/11/24, 8:11 AM
Location
baselMoney raised
$147 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Upmc Enterprises, Invus, Polaris Partners, Gilde Healthcare, Sofinnova Partners, Jeito Capital, Forbion, Eqt Life Sciences
Noema Pharma successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised to approximately $147 million. This financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.
Company Info
Location
basel, basel-stadt, switzerland
Additional Info
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025.
Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT Life Sciences, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.